Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

MediClin Aktie 1158721 / DE0006595101

31.07.2025 13:13:15

EQS-News: MEDICLIN reports positive interim results for the first half of 2025

EQS-News: MediClin AG / Key word(s): Half Year Report/Half Year Results
MEDICLIN reports positive interim results for the first half of 2025

31.07.2025 / 13:13 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 31 July 2025
MEDICLIN reports positive interim results for the first half of 2025
                                                                             
  • Group operating result amounts to EUR 22.4 mill. (6M 2024: EUR 11,9 mill.)
  • Consolidated group sales amounts to EUR 383.8 mill. (6M 2024: EUR 368.0 mill.)
  • Overall capacity utilisation stable at 86.1%
 
Offenburg, 31 July 2025: In the first half of 2025, MEDICLIN Aktiengesellschaft (ticker: MED; WKN 659 510) generated consolidated group sales of EUR 383.8 mill. This represents an increase of EUR 15.8 mill. or 4.3% compared with the first half of 2024. The Group operating result improved by EUR 10.4 mill. to EUR 22.4 mill. compared to the same period last year (6M 2024: EUR 11.9 mill.). The Group's overall capacity utilisation remained stable at 86.1% (6M 2024: 85.7%).

“We succeeded in maintaining our earnings power at a stable level and in increasing efficiency in the individual segments. The solid overall capacity utilisation and the increase in the group operating result underscore our sustainable growth strategy,” said Tino Fritz, CFO of MEDICLIN, commenting on the development in the first half of 2025.

Developments in the segments

In the Post-Acute segment, sales increased by 10.2% to EUR 257.0 mill. (6M 2024: EUR 233.3 mill.). The segment operating result rose by EUR 5.8 mill. to EUR 23.3 mill. (6M 2024: EUR 17.5 mill.). The cost of materials ratio fell by one percentage point to 20.1% (6M 2024: 21.1%). At EUR 51.6 mill., the absolute cost of materials was 4.8% above the previous year's figure (6M 2024: EUR 49.3 mill.). Personnel expenses increased by EUR 12.7 mill. or 10.1% to EUR 138.3 mill. compared with the first half of the previous year, mainly due to the usual salary increases for existing staff. The personnel expense ratio remained constant at 53.8%.

Developments in the Acute segment are driven by the sale of the former MEDICLIN Herzzentrum Coswig. Segment sales declined by EUR 8.6 mill. or 7.2%.  The cost of materials fell by 10.6% to EUR 31.0 mill. (6M 2024: EUR 34.7 mill.). The cost of materials as a percentage of revenue declined slightly to 27.8% (6M 2024: 28.9%). Personnel expenses amounted to EUR 68.6 mill., down 7.3% on the previous year (6M 2024: EUR 74.0 mill.). The personnel expense ratio remained virtually unchanged at 61.4% (6M 2024: 61.5%). Operating result improved by EUR 2.8 mill. or 71.5% to EUR 1.1 mill. (6M 2025: EUR –3.9 mill.).

Sales in the Care segment rose to EUR 12.4 mill. in the first half of 2025 (6M 2024: EUR 11.7 mill.), while the segment operating result was slightly below the prior-year period at EUR –0.3 mill. (6M 2024: EUR –0.1 mill.).

In the Service segment, sales increased by EUR 2.0 mill. to EUR 50.3 mill. (6M 2024: EUR 48.2 mill.). At EUR 0.5 mill., the segment operating result was EUR 2.0 mill. higher than in the same period of the previous year (6M 2024: EUR –1.6 mill.).

Outlook and current events

For the current financial year, the Management Board continues to expect an increase in consolidated group sales of between 2.0% and 5.0% and consolidated operating profit of between EUR 53.0 mill. and EUR 64.0 mill.

The interim report as of 30 June 2025 is available in German and English at www.mediclin.de as of today.

For more information:

MEDICLIN Aktiengesellschaft
Okenstrasse 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de
www.mediclin.de
About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and nine medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN - a company of the Asklepios Group

 


31.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstrasse 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2177630

 
End of News EQS News Service

2177630  31.07.2025 CET/CEST

Analysen zu MediClin AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

KI Aktien – Gewinner der Digitalisierung – Wall Street Live mit Tim Schäfer

In dieser Folge sprechen wir mit Tim Schäfer live aus New York über den aktuellen Stand der KI-Aktien. Sind die Kurse von Nvidia, Microsoft, Meta, Amazon, Alphabet und Apple noch gerechtfertigt – oder stehen wir kurz vor einer Spekulationsblase?

📈 Tim analysiert die Zahlen, Investitionen und Bewertungen der grossen Tech-Konzerne und zeigt, wie viel Kapital derzeit in KI-Infrastruktur fliesst. Zudem diskutieren wir, welche Randbereiche vom KI-Boom profitieren könnten – etwa Rechenzentren, Stromversorger oder Hardwarehersteller.

Themen im Video:
🔹Die „Magnificent 7“ im Check: Meta, Microsoft, Nvidia, Amazon, Alphabet, Apple
🔹Investitionen in KI: 71 Mrd. bei Meta, 120 Mrd. bei Microsoft
🔹Nvidia: Marktführer, aber extrem teuer
🔹Apple: Aufholjagd oder zu spät dran?
🔹Gefahr einer KI-Blase?
🔹Welche Alternativen bieten sich für Langfristinvestoren?
🔹Rechenzentren, Energieanbieter & Zulieferer im Fokus
🔹Wie Tim mit Rücksetzern und Seitwärtsphasen umgeht
🔹Erste Anzeichen für eine neue Superintelligenz?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

KI Aktien – Gewinner der Digitalisierung – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’831.04 19.25 S2S3NU
Short 13’072.32 13.92 BP9SUU
Short 13’587.68 8.77 BWCSGU
SMI-Kurs: 12’303.98 08.09.2025 15:24:58
Long 11’795.07 19.56 S69BTU
Long 11’534.82 13.77 BXGS2U
Long 11’023.53 8.80 BYCSSU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}